Gelesis
Manufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
501 Boylston St Ste 6102, Boston, Massac...Phone Number
(617) 456-4718Website
www.gelesis.comRevenue
$11.2 MillionStock Symbol
GLSIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Gelesis
Gelesis is a pharmaceutical company developing treatments for overweight and obese patients struggling with impaired-fasting glucose and diabetes. It is based in Boston, Massachusetts.Explore more
Gelesis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Gelesis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Gelesis has new funding data
Click to see if Gelesis had a recent Job posting/layoffs
Earning: See what the market has to say on Gelesis recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Gelesis
Check out if Gelesis is spiking on competitors!
Gelesis, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Gelesis has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Gelesis launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Gelesis
Compare insights from companies similar to Gelesis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Gelesis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Gelesis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Gelesis.
Gelesis financials insights
Gather financial insights about Gelesis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2006
Series A
$500K
2008
Unspecified
$16M
2011
Unspecified
$3.6M
Private Equity
$2.6M
2014
Unspecified
$12M
2015
Private Equity
$22M
Private Equity
$31.5M
2019
Grant
$10.6M
Private Equity
$63.4M
2020
Debt
$150K
Gelesis Tech Stack
A closer look at the technologies used by Gelesis
See more technologies
Most Recent Scoops
Left Company
Executive Move
Earnings
Sales
Left Company
Executive Move
Event
Events
Earnings
Sales
Gelesis News & Media
Gelesis’ Oral Treatment for Weight Management Showed Real-World Effectiveness in New Data Presented at the American Diabetes Association’s Annual Conference
BOSTON--(BUSINESS WIRE)---- $GLS #earnings--Gelesis, the maker of Plenity for weight management, presented a late-breaking poster presentation at the American Diabetes Association’s (ADA) 2023 annual meeting showing the real-world effectiveness of the company’s oral superabsorbent hydrogel across 894 people who were prescribed Plenity for weight management. Consistent with previous clinical studies, responders demonstrated clinically significant weight loss at 6 months. Plenity is an orally admiNYSE to Suspend Trading Immediately in Gelesis Holdings, Inc. (GLS) and Commence Delisting Proceedings
NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Gelesis Holdings, Inc. (the “Company”) — ticker symbol GLS — from the NYSE. Trading in the Company’s common stock will be suspended immediately. NYSE Regulation reached its decision to delist the Company’s common stock pursuant to Section 802.01B of the NYSE’s Listed Company Manual because theGelesis to Participate in the 25th Annual ICR Conference
BOSTON--(BUSINESS WIRE)---- $GLS #earnings--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today announced that the Company will participate in the 25th Annual ICR Conference in Orlando, Florida on Monday, January 9, 2023. Gelesis will host a presentation at 1:30 p.m. ET. The live webcast can be accessed on the “Events & Presentations” section of the Gelesis Investor Relations website at https://ir.gelesis.com/. The webcast will also be archived and available for replay. AboutNYSE to Suspend Trading Immediately in Warrants of Gelesis Holdings, Inc. (GLS WS) and Commence Delisting Proceedings
NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants of Gelesis Holdings, Inc. (the “Company”), each whole warrant exercisable for one share of common stock — ticker symbol GLS WS — from the NYSE. Trading in the Company’s warrants will be suspended immediately. Trading in the Company’s common stock — ticker symbol GLS — will continue on
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Gelesis
Sign Up For FreeTo access detailed company insights
Gelesis is a pharmaceutical company developing treatments for overweight and obese patients struggling with impaired-fasting glucose and diabetes. It is based in Boston, Massachusetts.... Read More
